GSDMD and cardiac hypertrophy: This study showed that NBP, which was approved for ischaemic stroke by the State Food and Drug Administration in China in 2002, provides protection against pressure overload-mediated deleterious myocardial hypertrophy by directly binding to GSDMD-N protein and reducing GSDMD-mediated inflammation (Figure 5E).